S&P Futures
4,216.25 +6.50 (+0.15%) Dow Futures
33,342.00 +38.00 (+0.11%) Nasdaq Futures
13,343.50 +32.25 (+0.24%) Russell 2000 Futures
1,980.30 +4.00 (+0.20%) Crude Oil
93.82 -0.52 (-0.55%) Gold
1,807.10 -0.10 (-0.01%)
CARsgen Therapeutics Holdings Limited (2171.HK)
Chart Events
Performance Outlook
| Previous Close | 18.160 |
| Open | 18.200 |
| Bid | 17.940 x N/A |
| Ask | 18.060 x N/A |
| Day's Range | 17.620 - 18.480 |
| 52 Week Range | 9.680 - 57.250 |
| Volume | |
| Avg. Volume | 1,671,532 |
| Market Cap | 10.246B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.01 |
- PR Newswire
CARsgen Appoints Dr. Hua Jiang as Executive Director
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.
- PR Newswire
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the Company presented two posters with study results for CT041, an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2). The two posters included (1) results from the multicenter Phase 1b CT041 trial in the U
- PR Newswire
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which is one of the top international medical journals in the Nature Portfolio (2-year Impact Factor of 53.44).
